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Background
Both population and ultra-deep sequencing (UDS) of the
HIV-1 V3 loop are useful in selecting candidates for
maraviroc (MVC) therapy. We used mathematical mod-
eling to determine that patients whose non-R5 HIV
comprises <2% of the viral population by UDS are likely
to respond to a MVC-containing regimen. However, the
predictive value of absolute amount of non-R5 HIV is
unknown.
Objective
To determine whether non-R5 viral load contributes to
predicting response to a MVC-containing regimen.
Methods
Patients enrolled in the MERIT study (MVC or efavir-
enz plus zidovudine/lamivudine in treatment-naïve
patients) with R5 virus at screening (by original Trofile
assay) and randomized to the twice-daily MVC arm
were included. UDS was performed with a 454/Roche
GS-FLX instrument. Tropism was predicted using the
“geno2pheno” co-receptor algorithm (g2p). A sample
was considered R5 if <2% of variants had a score below
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descriptive statistics and mathematical modeling.
Results
Samples for 343 patients (308 R5, 35 non-R5) were
available. Baseline median CD4 and mean viral load
(VL) were 247 and 232 cells/µL and 4.9 and 4.6 log10 c/
mL in patients with R5 and non-R5 virus. No CXCR4-
using viruses were detected in 249/343 (73%) patients.
Among the 94 patients with detectable CXCR4-use,
median (q25, q75) percent and absolute levels of
CXCR4-using viruses were 0.8% (0.4-8.1) and 2.9 (2.3-
3.5) log10 c/mL, respectively. Week 48 virologic
responses are shown in Table 1.
In univariate models, baseline CD4 and percent of
CXCR4-using virus were not significant predictors of
week 48 response (p=0.12; p=0.26); VL and absolute
amount of CXCR4-using virus were significant (p=0.02;
p=0.03) and were included in the multivariate model
(p=0.02 for both in final model).
Conclusion
In MVC-treated patients in the MERIT study, baseline
VL and absolute amount of CXCR4-using virus were
predictive of Week 48 response. It is possible that total
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Table 1
Baseline level of CXCR4-using
virus
<50 HIV-1 RNA c/mL at Week 48, n/N
(%)
Percentage
<2% 207/308 (67.2)
2%—<10% 7/13 (53.8)
≤10% 11/22 (50.0)
Amount (log10 copies/mL)
<1.0 171/251 (68.1)
1.0—<2.0 12/15 (80.0)
2.0—<3.0 23/36 (63.9)
3.0—<4.0 13/25 (52.0)
≤4.0 6/16 (37.5)
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virus in predicting response to regimens containing a
CCR5 antagonist.
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